

Special Issue

New Small Molecule Inhibitors Used in Cancers

Message from the Guest Editors

Over the past few years, a broad spectrum of small molecules has been developed for anticancer agents and approved for the treatment of several types of tumor. In particular, small-molecule-targeted drugs show advantages in some clinical aspects, such as pharmacokinetic (PK) properties, lower toxicity than chemotherapy, costs, and patient compliance. The targets of such molecules cover large class of receptors, epigenetic regulatory proteins, and DNA damage repair enzymes and proteasomes. The aim of this Special Issue is to present innovative and scientifically robust manuscript to promote advances in personalized cancer therapy, in addition to comprehensive reviews showing the challenges and future perspectives in the field.

Guest Editors

Dr. Francesca Iommelli

Institute of Biostructures and Bioimaging, National Research Council, 80145 Naples, Italy

Dr. Viviana De Rosa

Institute of Biostructures and Bioimaging, National Research Council, 80145 Naples, Italy

Deadline for manuscript submissions

closed (30 April 2024)



Medicina

an Open Access Journal
Published by MDPI

Impact Factor 2.4
CiteScore 4.6
Indexed in PubMed



mdpi.com/si/189160

Medicina
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicina@mdpi.com

[mdpi.com/journal/
medicina](https://mdpi.com/journal/medicina)





Medicina

an Open Access Journal
Published by MDPI

Impact Factor 2.4
CiteScore 4.6
Indexed in PubMed



[mdpi.com/journal/
medicina](https://mdpi.com/journal/medicina)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius
Medical Academy, Lithuanian University of Health Sciences, Kaunas,
Lithuania

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)